PriceTargets.com logo

Hyperliquid Strategies - PURR Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $7.23
  • Forecasted Upside: 69.60%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$4.26 As of 02/12/2026 05:00 PM ET
▼ -0.28 (-6.17%)

This chart shows the closing price for PURR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Hyperliquid Strategies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PURR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PURR

Analyst Price Target is $7.23
▲ +69.60% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Hyperliquid Strategies in the last 3 months. The average price target is $7.23, with a high forecast of $8.45 and a low forecast of $6.00. The average price target represents a 69.60% upside from the last price of $4.26.

This chart shows the closing price for PURR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Hyperliquid Strategies. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/19/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/17/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/18/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/16/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/14/2025
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/13/2026
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/12/2026

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
2/12/2026Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$5.00 ➝ $6.00
2/12/2026Chardan CapitalBoost TargetBuy ➝ Buy$8.15 ➝ $8.45
(Data available from 2/12/2021 forward)

News Sentiment Rating

0.40 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/17/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/16/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/15/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/15/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/14/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/14/2025
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/13/2026
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/12/2026

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Hyperliquid Strategies logo
Hyperliquid Strategies Inc is a digital asset treasury company whose primary focus is to maximize shareholder value through accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance. Hyperliquid Strategies Inc, formerly known as Sonnet BioTherapeutics Holdings Inc., is based in NEW YORK.
Read More

Today's Range

Now: $4.26
Low: $4.13
High: $4.90

50 Day Range

MA: N/A

52 Week Range

Now: $4.26
Low: $3.01
High: $5.78

Volume

3,580,203 shs

Average Volume

3,200,156 shs

Market Capitalization

$541.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.57

Frequently Asked Questions

What sell-side analysts currently cover shares of Hyperliquid Strategies?

The following sell-side analysts have issued research reports on Hyperliquid Strategies in the last year: Chardan Capital.
View the latest analyst ratings for PURR.

What is the current price target for Hyperliquid Strategies?

0 Wall Street analysts have set twelve-month price targets for Hyperliquid Strategies in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Hyperliquid Strategies in the next year.
View the latest price targets for PURR.

What is the current consensus analyst rating for Hyperliquid Strategies?

Hyperliquid Strategies currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for PURR.

What other companies compete with Hyperliquid Strategies?

Other companies that are similar to Hyperliquid Strategies include Mineralys Therapeutics, Telix Pharmaceuticals, Dyne Therapeutics, Adaptive Biotechnologies and Ultragenyx Pharmaceutical. Learn More about companies similar to Hyperliquid Strategies.

How do I contact Hyperliquid Strategies' investor relations team?

Hyperliquid Strategies' physical mailing address is 477 MADISON AVENUE 22ND FLOOR, C/O HYPERLIQUID STRATEGIES INC, NEW YORK, NY, 10022. The company's listed phone number is (212) 883-4330 and its investor relations email address is [email protected]. The official website for Hyperliquid Strategies is www.sonnetbio.com. Learn More about contacing Hyperliquid Strategies investor relations.